Monique Spillman
Sourced from institutional research profiles (UAMS TRI or ARA).
Professor
Faculty Researcher
COM | Obstetrics & Gynecology
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Monique Spillman's research focuses on maternal and perinatal health, specifically investigating interventions to improve outcomes for mothers and newborns. Her work examines the impact of various factors on the health and development of infants, with a particular emphasis on understanding and addressing disparities in maternal and child health outcomes. Spillman's research aims to contribute to evidence-based practices in obstetrics and gynecology.
Metrics
- h-index: 26
- Publications: 152
- Citations: 3,324
Selected Publications
-
Comparison of cost of endometrial cancer staging between robotic and vNOTES techniques (2026)
-
A pilot study utilizing hypothermia to reduce chemotherapy-induced peripheral neuropathy (2026)
-
Abstract 2589: Prospective verification of OvaPrint and multi-omic profiling for precise adnexal mass classification (2026)
-
Polypoid endometriosis with endometrioid intraepithelial neoplasia mimicking malignancy: a rare case of a postmenopausal pelvic mass (2026)
-
Uterus Transplant (2024)
-
Sentinel lymph node biopsy for early stage vulvar squamous cell carcinoma (2024)
-
Abstract B040: OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer (2024)
-
Sentinel Lymph Node Biopsy for Early Stage Vulvar Squamous Cell Carcinoma (2024)
-
OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer (2023)
-
OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer (2023)
Collaboration Network
Top Collaborators
- OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
- OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer
- Abstract B040: OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer
- OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
- OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer
- Abstract B040: OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer
- OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
- OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer
- Abstract B040: OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer
- OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
- OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer
- Abstract B040: OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer
- OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
- OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer
- Abstract B040: OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer
- OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
- OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer
- Abstract B040: OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer
- OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
- OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer
- Abstract B040: OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer
- OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
- OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer
- Abstract B040: OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer
- OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
- OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer
- Abstract B040: OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer
- OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
- OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer
- OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
- Abstract B040: OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer
- OvaPrint™ – a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer
- Sentinel Lymph Node Biopsy for Early Stage Vulvar Squamous Cell Carcinoma
- Sentinel Lymph Node Biopsy for Early Stage Vulvar Squamous Cell Carcinoma
- Sentinel Lymph Node Biopsy for Early Stage Vulvar Squamous Cell Carcinoma
Similar Researchers
Based on overlapping research topics